158-OR: Major Adverse Cardiovascular Events for Kidney Disease Patients Treated with Metformin or Sulfonylurea

158-OR: Major Adverse Cardiovascular Events for Kidney Disease Patients Treated with Metformin or Sulfonylurea

Background: Safety concerns limit metformin use in kidney disease. We compared major adverse cardiovascular events (MACE) for metformin or sulfonylureas users with reduced glomerular filtration rate (GFR). Methods: A retrospective cohort combined Veterans Administration, Medicare, and National Death...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser: ROUMIE, CHRISTIANNE, CHIPMAN, JONATHAN J., MIN, JEA YOUNG, HUNG, ADRIANA M., HACKSTADT, AMBER J., GREEVY, ROBERT A., GRIJALVA, CARLOS G., ELASY, TOM, GRIFFIN, MARIE R.
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Cerebral infarction
Creatinine
Death
Glomerular filtration rate
Ischemia
Kidney diseases
Metformin
Myocardial infarction
Sulfonylurea
Transient ischemic attack
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Safety concerns limit metformin use in kidney disease. We compared major adverse cardiovascular events (MACE) for metformin or sulfonylureas users with reduced glomerular filtration rate (GFR). Methods: A retrospective cohort combined Veterans Administration, Medicare, and National Death Index databases. Metformin or sulfonylurea users were followed from renal threshold (GFR
ISSN:0012-1797
1939-327X
DOI:10.2337/db19-158-OR